Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population

Clinical Infectious Diseases

Volumn 56, Issue 3, 2013, Pages 315-321

  Tseng, Hung Fu ^a   Sy, Lina S ^a   Qian, Lei ^a   Marcy, S Michael ^a   Jackson, Lisa A ^b   Glanz, Jason ^a   Nordin, Jim ^c   Baxter, Roger ^a   Naleway, Allison ^a   Donahue, James ^d   Weintraub, Eric ^e   Jacobsen, Steven J ^a  

^a KAISER PERMANENTE   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^d MARSHFIELD CLINIC   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

adult vaccination; matched cohort study; pertussis prevention; Tdap vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ADULT; ANAPHYLAXIS; ARTICLE; BRACHIAL PLEXUS NEUROPATHY; BRAIN DISEASE; COHORT ANALYSIS; CRANIAL NEUROPATHY; DIPHTHERIA; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENCEPHALITIS; GUILLAIN BARRE SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MENINGITIS; OFF LABEL DRUG USE; PARALYSIS; PERTUSSIS; PRIORITY JOURNAL; TETANUS; UNITED STATES; VACCINATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; DIPHTHERIA; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HUMANS; OFF-LABEL USE; TETANUS; TIME FACTORS; UNITED STATES; VACCINATION; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 84872312670     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis871     Document Type: Article

References (23)

1. Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012; 54:1730-5.
2. Wendelboe AM, Njamkepo E, Bourillon A, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007; 26:293-9.
3. Centers for Disease Control and Prevention. Final 2009 reports of nationally notifiable infectious diseases. MMWR Morbid Mortal Wkly Rep 2010; 59:1025-39.
4. California Department of Public Health. Pertussis report, November 9, 2010. Available at: http://www.cdph.ca.gov/programs/immunize/Documents/ PertussisReport201011-09.pdf. Accessed 3 September 2012.
5. Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. MMWR Recomm Rep 2006; 55(RR-03):1-34.
6. Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine. MMWR Recomm Rep 2006; 55(RR-17):1-33.
7. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morbid Mortal Wkly Rep 2011; 60:13-5.
8. Weldeselassie YG, Whitaker HJ, Farrington CP. Use of the selfcontrolled case-series method in vaccine safety studies: review and recommendations for best practice. Epidemiol Infect 2011; 139:1805-17.
9. Whitaker HJ, Hocine MN, Farrington CP. The methodology of selfcontrolled case series studies. Stat Methods Med Res 2009; 18:7-26.
10. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006;25:1768-97.
11. Baggs J, Gee J, Lewis E, et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics 2011; 127(suppl 1): S45-53.
12. California Department of Public Health. Pertussis vaccination recommendations 2010. Available at: http://www.eziz.org/PDF/CDPH% 20Pertussis%20Immunization%20Policy%20July%202010.pdf. Accessed 31 October 2010.
13. Jackson LA, Yu O, Nelson J, et al. Risk of medically attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: a Vaccine Safety Datalink study. Vaccine 2009; 27:4912-6.
14. Yih WK, Nordin JD, Kulldorff M, et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine 2009; 27:4257-62.
15. Stratton K, Ford A, Rusch E, Clayton EW. Committee to Review Adverse Effects of Vaccines, Institute of Medicine. Adverse effects of vaccines: evidence and causality. Washington, DC: The National Academies Press, 2012.
16. Stratton KR, Howe CJ, Johnston RB Jr. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 1994; 271:1602-5.
17. Sanofi Pasteur. Package insert: tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed. Available at: http://www.fda.gov/ downloads/BiologicsBloodVaccines/Vaccines/Approved Products/UCM142764.pdf. Accessed 31 October 2010.
18. GlaxoSmithKline Biologicals. Prescribing information: Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed). Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/UCM152842.pdf. Accessed 31 October 2010.
19. Moro PL, Yue X, Lewis P, Haber P, Broder K. Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010. Vaccine 2011; 29:9404-8.
20. Lloyd JC, Haber P, Mootrey GT, Braun MM, Rhodes PH, Chen RT. Adverse event reporting rates following tetanus-diphtheria and tetanus toxoid vaccinations: data from the Vaccine Adverse Event Reporting System (VAERS), 1991-1997. Vaccine 2003; 21:3746-50.
21. Jackson LA, Yu O, Nelson JC, et al. Injection site and risk of medically attended local reactions to acellular pertussis vaccine. Pediatrics 2011; 127:e581-7.
22. Talbot EA, Brown KH, Kirkland KB, Baughman AL, Halperin SA, Broder KR. The safety of immunizing with tetanus-diphtheriaacellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine 2010; 28:8001-7.
23. Beytout J, Launay O, Guiso N, et al. Safety of Tdap-IPV given one month after Td-IPV booster in healthy young adults: a placebocontrolled trial. Hum Vaccin 2009; 5:315-21.